[Effects of postoperative chemotherapy on the prognosis of patients with high-risk early stage endometrial cancer].
OBJECTIVE
To investigate the effects of adjuvant chemotherapy for patients with high-risk stage I and II (early stage) endometrial cancer.


METHODS
From Jan. 1994 to Jun. 2007, 106 cases with early stage high-risk endometrial cancer were treated in Peking University First Hospital and were divided into two groups based with postoperative adjuvant chemotherapy (ACT group, 66 cases) and without adjuvant chemotherapy (control group, 40 cases). The 5-year survival rates was calculated by Kaplan-Meier method. Prognosis factors were further determined by univariate analysis and Cox proportional hazards models.


RESULTS
The 5-year survival rate in the ACT group was significantly higher than that in control group (94% and 81%, P<0.05). On the univariate analysis, the 5-year survival rate of patients received four or more cycles combined chemotherapy was higher than that of cases less than four cycles chemotherapy (100% and 86%, P<0.05). While, it were not significant difference in age, stage, histology, grade, radiotherapy alone, chemotherapy combined radiotherapy or progestin hormonal therapy (P>0.05). On the multivariate analysis, adjuvant chemotherapy was found to affect independent prognostic covariates on early stage cases (P<0.05).


CONCLUSIONS
Postoperative adjuvant chemotherapy maybe improve the prognosis of patients with high-risk early stage endometrial cancer, which need to be further study by prospective randomized trials.
Wen
Hong-wu
HW
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China. wenhongwu3184@sohu.com
Tian
Fen
F
Ma
Li
L
Liao
Qin-ping
QP
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin